- <![CDATA[The OncFive: Top Oncology Articles for the Week of 5/3]]><![CDATA[The FDA clears zenocutuzumab in NRG1 fusion+ cholangiocarcinoma, accepts a taletrectinib NDA in ROS1+ NSCLC for review, and more.]]>onclive · 2mo ago↗ source
- <![CDATA[Dr Randall on Long-Term Responses and Functional Benefits With Pimicotinib in TGCT]]><![CDATA[R. Lor Randall, MD, FACS discusses safety and efficacy data from the MANEUVER trial, which evaluated pimicotinib in TGCT.]]>onclive · 2mo ago↗ source
- <![CDATA[Post–T-DXd Sacituzumab Govitecan Plus Trastuzumab Yields Low ORR in HER2+ Metastatic Breast Cancer]]><![CDATA[Sacituzumab govitecan plus trastuzumab following T-DXd did not meet the primary end point of the SATEEN trial in HER2+ metastatic breast cancer.]]>onclive